Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases

Patent metadata

Field	Value
Publication number	US-10208071-B2
Application number	US-201715656766-A
Country	US
Kind code	B2
Filing date	Jul 21, 2017
Priority date	Mar 6, 2013
Publication date	Feb 19, 2019
Grant date	Feb 19, 2019

Abstract

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.

First claim

What is claimed is:

1. A method of treating an ocular inflammatory disease in a subject in need of such treatment, wherein the method comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one formyl peptide receptor 2 (FPR2) agonist to the subject;
wherein the ocular inflammatory disease is selected from the group consisting of uveitis, dry eye, keratitis, allergic eye disease, infectious keratitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, retinitis, choroiditis, acute multifocal placoid pigment epitheliopathy, Behcet's disease, post-surgical corneal wound healing, wet age-related macular degeneration (ARMD) and dry ARMD; and
wherein the agonist is a compound represented by Formula I, or a pharmaceutically acceptable salt thereof:

wherein:
R 1 is sec-butyl, C 6-10 aryl, —CH 2 —(C 6-10 )aryl, —CH 2 -heterocycle, C 4-8 cycloalkyl, C 3-8 cycloalkenyl or heterocycle;
R 2 is halogen or methyl;
R 3 is halogen;
R 4 is H, methyl or halogen;
R 5 is OR 6 or NH 2 ; and
R 6 is H or C 2-4 alkyl;
or wherein the agonist is a compound selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

2. The method of claim 1 , wherein the agonist is a compound of Formula I.

3. The method of claim 2 , wherein the compound is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

4. The method of claim 1 , wherein the agonist is a compound selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

5. The method of claim 4 , wherein the compound has the following structure:

or a pharmaceutically acceptable salt thereof.

Assignees

• Allergan Inc

Inventors

• Beard Richard L
• Donello John E
• Viswanath Veena

Classifications

• A61P29/02

  without antiinflammatory effect · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P27/00

  Drugs for disorders of the senses · CPC title

• A61K31/197

  the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205) · CPC title